GKOS Stock Risk & Deep Value Analysis
Glaukos Corp
DVR Score
out of 10
What You Need to Know About GKOS Stock
We analyzed Glaukos Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GKOS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
GKOS Risk Analysis & Red Flags
What Could Go Wrong
While Glaukos's revenue growth is robust, the company continues to operate at a net loss. A significant slowdown in iDose TR adoption or unforeseen competitive pressure could delay its path to sustainable profitability, potentially necessitating future capital raises that might dilute existing shareholders.
Risk Matrix
Overall
Moderate
Financial
Low-Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Low-Medium
Red Flags
- ⚠
CFO Alex R. Thurman sold 4,657 shares totaling ~$490k in March 2026, indicating continued insider selling.
- ⚠
Despite improving, the company is still reporting net losses, requiring careful monitoring of cash burn.
- ⚠
Lack of detailed institutional ownership changes or recent analyst ratings in current research makes broader sentiment assessment more speculative.
Upcoming Risk Events
- 📅
Q2 2026 earnings miss or downward revision of FY2026 guidance
- 📅
Unexpected competitive product launches in MIGS or sustained drug delivery
- 📅
Increased scrutiny or delays in regulatory approvals for future pipeline products
When to Reconsider
- 🚪
Exit if quarterly revenue growth decelerates below 25% YoY for two consecutive quarters.
- 🚪
Sell if GAAP gross margin falls below 75% for two consecutive quarters, signaling pricing pressure or cost inefficiencies.
- 🚪
Re-evaluate position if significant executive turnover or unexpected negative regulatory news emerges.
Unlock GKOS Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Glaukos is a high-growth leader in the ophthalmic medical device sector, uniquely positioned for a 10x return over the next 3-5 years. This thesis is driven by the rapid commercialization and market adoption of iDose TR, which is expanding the total addressable market for glaucoma treatment through sustained drug delivery, coupled with strong execution, a pristine balance sheet, and a clear path to profitability.
Is GKOS Stock Undervalued?
Unlock the full AI analysis for GKOS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
GKOS Price Targets & Strategy
12-Month Target
$175.00
Bull Case
$250.00
Bear Case
$100.00
Valuation Basis
Based on 12.5x forward P/S applied to estimated FY27 sales of $825.5M.
Entry Strategy
Consider dollar-cost averaging in the $125-$135 range, establishing a core position around current price and adding on dips towards the 50-day SMA if support is found.
Exit Strategy
Initiate profit-taking around $200-$220. Set a stop-loss order at $115 to protect against significant downside while allowing for volatility.
Portfolio Allocation
7-10% for aggressive risk tolerance; 3-5% for moderate risk tolerance.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is GKOS Financially Healthy?
Valuation
P/E Ratio
-25.50
Forward P/E
300.23
Profitability
Gross Margin
77.97%
Operating Margin
-39.33%
Net Margin
-36.99%
Return on Equity
-25.41%
Revenue Growth
32.33%
EPS
$-3.27
Balance Sheet
Current Ratio
4.69
Quick Ratio
3.82
Debt/Equity
0.11
Cash & Equivalents
$280.50M
Other
Beta (Volatility)
0.90
Does GKOS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Glaukos's moat is primarily driven by its innovative intellectual property, particularly the iDose TR which offers a novel approach to glaucoma management. The clinical data and established surgeon trust provide significant durability against new entrants, while continuous R&D aims to extend its lead.
Moat Erosion Risks
- •Expiration of key patents, allowing generic or biosimilar competition.
- •Emergence of superior, less invasive, or significantly cheaper technologies from larger competitors.
- •Intensified competition in the MIGS space leading to pricing pressure.
GKOS Competitive Moat Analysis
Sign up to see competitive advantages
GKOS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral-to-Bullish. Strong Q1 results and raised guidance are likely to generate positive sentiment and discussions among retail investors.
Institutional Sentiment
Positive momentum. The strong Q1 earnings beat and raised guidance are highly likely to lead to positive revisions from analysts and potential increased institutional interest, reversing some of the previous 'cautious outlook'.
Insider Activity (Form 4)
CFO Alex R. Thurman sold 4,657 shares between March 17-25, 2026, totaling approximately $490,000. No insider buys were reported in the last 90 days.
Options Flow
Normal options activity (no specific unusual options flow data was provided in the research).
Earnings Intelligence
Next Earnings
Estimated late July 2026 (for Q2 2026)
Surprise Probability
Medium-High
Historical Earnings Pattern
Based on the Q1 2026 report, Glaukos's stock tends to react positively to beats on both top and bottom lines, especially when accompanied by raised forward guidance.
Key Metrics to Watch
Competitive Position
Top Competitor
Alcon (ALC)
Market Share Trend
Gaining significant market share in the MIGS space, particularly with the rapid adoption of iDose TR, while maintaining leadership with iStent.
Valuation vs Peers
Glaukos trades at a premium to many established medical device companies on a P/S basis, justified by its higher growth rate and innovative market position, particularly in the emerging sustained drug delivery segment.
Competitive Advantages
- •Proprietary IP and first-mover advantage in Micro-Invasive Glaucoma Surgery (MIGS) with iStent.
- •Unique sustained drug delivery platform (iDose TR) creating a new market segment.
- •Established relationships and strong brand recognition among ophthalmologists.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive GKOS Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (Estimated late July 2026)
- •Continued accelerated ramp-up of iDose TR commercialization
- •Full commercial impact of Epioxa's permanent J-code
Medium-Term (6-18 months)
- •Pipeline advancements for new product candidates (e.g., PreserFlo MicroShunt expansion)
- •Potential geographic expansion of iDose TR and Epioxa into new international markets
- •Achievement of positive operating cash flow and reduced net losses
Long-Term (18+ months)
- •Establishment of iDose TR as standard of care for sustained glaucoma therapy
- •Disruption of traditional eye drop market for glaucoma management
- •Expansion into other chronic ocular disease states with sustained drug delivery platforms
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for GKOS?
- ✓
Sustained iDose TR sales exceeding analyst expectations with accelerating growth rates.
- ✓
Consistent improvement in non-GAAP operating and net margins, leading to positive free cash flow generation.
- ✓
Positive clinical trial readouts or regulatory milestones for pipeline products.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Glaukos Corp Makes Money
Glaukos Corp develops and sells innovative medical devices and sustained drug delivery systems for treating chronic eye diseases, primarily glaucoma and corneal disorders. Its revenue comes from the sales of its proprietary products, such as the iStent for micro-invasive glaucoma surgery (MIGS) and iDose TR, which continuously delivers medication for months after a single implantation, directly to eye surgeons and clinics. The company aims to provide less invasive, more effective, and convenient solutions for patients, generating recurring sales through product adoption and utilization.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Glaukos Corp (GKOS)?
As of May 9, 2026, Glaukos Corp has a DVR Score of 8.4 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Glaukos Corp?
Glaukos Corp's market capitalization is approximately $7.9B..
What is the risk level for GKOS stock?
Our analysis rates Glaukos Corp's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of GKOS?
Glaukos Corp currently has a price-to-earnings (P/E) ratio of -25.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Glaukos Corp's revenue growing?
Glaukos Corp has reported revenue growth of 32.3%. The company is showing strong top-line momentum.
Is GKOS stock profitable?
Glaukos Corp has a profit margin of -37.0%. The company is currently unprofitable.
How often is the GKOS DVR analysis updated?
Our AI-powered analysis of Glaukos Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 9, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for GKOS (Glaukos Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.